Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 34.34 -2.89 (-7.76%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ionis Pharmaceuticals New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA October 08, 2024 From Biogen Inc. Via GlobeNewswire Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations September 04, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA September 04, 2024 From Biogen Inc. Via GlobeNewswire Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 From Biogen Inc. Via GlobeNewswire Are These 5 Undervalued Stocks Ready to Break Out? March 08, 2024 Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. Via MarketBeat New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio January 08, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies November 16, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day October 02, 2023 From Praxis Precision Medicines, Inc. Via GlobeNewswire Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action September 26, 2023 Via Investor Brand Network New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy June 30, 2023 From Biogen Inc. Via GlobeNewswire Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness January 09, 2023 From Royalty Pharma plc Via GlobeNewswire Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies January 04, 2023 From Biogen Inc. Via GlobeNewswire Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026 June 22, 2022 Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... Via FinancialNewsMedia Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
